|
Don't come to Xencor if you need the hem adjusted on your new pants: The company tailors proteins, not pants. Xencor is developing therapeutics for cancer, inflammatory ailments, and autoimmune diseases. The company engineers antibodies using its Protein Design Automation (PDA) technology, which allows for the specific targeting of diseased cells. Its drug candidates aim to treat cancerous conditions such as Hodgkin's lymphoma, T-cell lymphomas, and B-cell malignancies, as well as other autoimmune diseases. Research partners include Centocor, Genentech, Eli Lilly, and Human Geonome Sciences.
|
| | | Contact Information | |
Address: |
111 W. Lemon Ave.
Monrovia, CA 91016
| | Phone: | 626-305-5900 | | Fax: | 626-305-0350 |
|
|
Key People
| | • |
Chairman:
David R. King
| | • |
President, CEO, and Director:
Bassil I. Dahiyat
| | • |
Senior Director, Finance:
John J. Kuch
|
|
|
